F2G gets re­ject­ed by the FDA, which wants more da­ta be­fore it will ap­prove an­ti­fun­gal drug, com­pa­ny says

The an­ti­fun­gal-fo­cused biotech F2G has more work to do be­fore it will be able to get its drug for in­va­sive fun­gal in­fec­tions ap­proved by US reg­u­la­tors.

On Mon­day, the Man­ches­ter, UK-based biotech said that the FDA had is­sued a com­plete re­sponse let­ter for its ex­per­i­men­tal drug olo­rofim. The agency “was not able to ap­prove olo­rofim at this time” and wants more da­ta and analy­ses be­fore it will act, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER